DOSEF
Price
$0.14
Change
-$0.36 (-72.00%)
Updated
Dec 3 closing price
MNPR
Price
$30.25
Change
-$0.43 (-1.40%)
Updated
Dec 18, 04:59 PM (EDT)
Ad is loading...

DOSEF vs MNPR

Header iconDOSEF vs MNPR Comparison
Open Charts DOSEF vs MNPRBanner chart's image
Doseology Sciences
Price$0.14
Change-$0.36 (-72.00%)
Volume$2K
CapitalizationN/A
Monopar Therapeutics
Price$30.25
Change-$0.43 (-1.40%)
Volume$100
CapitalizationN/A
DOSEF vs MNPR Comparison Chart
Loading...
DOSEF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DOSEF vs. MNPR commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DOSEF is a Hold and MNPR is a Buy.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (DOSEF: $0.14 vs. MNPR: $30.68)
Brand notoriety: DOSEF and MNPR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DOSEF: 199% vs. MNPR: 16%
Market capitalization -- DOSEF: $463.68K vs. MNPR: $161.92M
DOSEF [@Biotechnology] is valued at $463.68K. MNPR’s [@Biotechnology] market capitalization is $161.92M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DOSEF’s FA Score shows that 1 FA rating(s) are green whileMNPR’s FA Score has 0 green FA rating(s).

  • DOSEF’s FA Score: 1 green, 4 red.
  • MNPR’s FA Score: 0 green, 5 red.
According to our system of comparison, both DOSEF and MNPR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DOSEF’s TA Score shows that 4 TA indicator(s) are bullish while MNPR’s TA Score has 4 bullish TA indicator(s).

  • DOSEF’s TA Score: 4 bullish, 4 bearish.
  • MNPR’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, MNPR is a better buy in the short-term than DOSEF.

Price Growth

DOSEF (@Biotechnology) experienced а 0.00% price change this week, while MNPR (@Biotechnology) price change was +34.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.92%, and the average quarterly price growth was +0.65%.

Reported Earning Dates

MNPR is expected to report earnings on Nov 08, 2024.

Industries' Descriptions

@Biotechnology (-6.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MNPR($158M) has a higher market cap than DOSEF($461K). MNPR YTD gains are higher at: 1703.645 vs. DOSEF (-37.277). DOSEF has higher annual earnings (EBITDA): -1.3M vs. MNPR (-7M). DOSEF has higher revenues than MNPR: DOSEF (104K) vs MNPR (0).
DOSEFMNPRDOSEF / MNPR
Capitalization461K158M0%
EBITDA-1.3M-7M19%
Gain YTD-37.2771703.645-2%
P/E RatioN/AN/A-
Revenue104K0-
Total CashN/A6.02M-
Total DebtN/A0-
TECHNICAL ANALYSIS
Technical Analysis
DOSEFMNPR
RSI
ODDS (%)
Bullish Trend 2 days ago
55%
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
63%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 6 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
47%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
50%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
N/A
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
60%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
41%
Bullish Trend 2 days ago
76%
View a ticker or compare two or three
Ad is loading...
DOSEF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PRRCX12.32N/A
N/A
Pioneer Equity Premium Income C
MGIFX10.72N/A
N/A
Mondrian Global Listed Infrastructure
MINVX31.57-0.17
-0.54%
Madison Investors Y
FSLCX19.14-0.29
-1.49%
Fidelity Small Cap Stock
VVOSX22.45-0.46
-2.01%
Invesco Value Opportunities R6

DOSEF and

Correlation & Price change

A.I.dvisor tells us that DOSEF and MNPR have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DOSEF and MNPR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DOSEF
1D Price
Change %
DOSEF100%
N/A
MNPR - DOSEF
24%
Poorly correlated
+14.91%
AKRO - DOSEF
23%
Poorly correlated
+4.72%
SGMT - DOSEF
21%
Poorly correlated
+3.66%
ADAG - DOSEF
21%
Poorly correlated
+3.45%
CLRPF - DOSEF
12%
Poorly correlated
-0.21%
More

MNPR and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNPR has been loosely correlated with QNCX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if MNPR jumps, then QNCX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNPR
1D Price
Change %
MNPR100%
+14.91%
QNCX - MNPR
36%
Loosely correlated
-3.66%
AKBLF - MNPR
29%
Poorly correlated
N/A
LOGC - MNPR
28%
Poorly correlated
-3.62%
BDRX - MNPR
26%
Poorly correlated
+0.96%
DOSEF - MNPR
24%
Poorly correlated
N/A
More